Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet Neurology
Fecha de publicación: 06 November 2017
DOI: http://dx.doi.org/10.1016/S1474-4422(17)30378-2
Autores: Prof Vera Bril, MD, Nan van Geloven, PhD, Prof Hans-Peter Hartung, MD, Prof Richard A Lewis, MD, Prof Gen Sobue, MD, John-Philip Lawo, Diplom, Michaela Praus, Diplom, Orell Mielke, MD, Billie L Durn, BS, Prof David R Cornblath, MD, Ingemar S J Merkies,Prof Ivo N van Schaik, MD.
Objective: Approximately two-thirds of patients with chronic inflammatory demyelinating polyneuropathy (CIDP) need long-term intravenous immunoglobulin. Subcutaneous immunoglobulin (SCIg) is an alternative option for immunoglobulin delivery, but has not previously been investigated in a large trial of CIDP. The PATH study compared relapse rates in patients given SCIg versus placebo.
